Acanthamoeba keratitis: Persistent organisms without inflammation after 1 year of topical chlorhexidine

Cornea

Volumn 27, Issue 2, 2008, Pages 246-248

  Gooi, Patrick ^a   Lee Wing, Matthew ^a   Brownstein, Seymour ^a,b   El Defrawy, Sherif ^a   Jackson, W Bruce ^a   Mintsioulis, George ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Acanthamoeba; Chlorhexidine; Corneal infection; Histopathology; Keratitis

Indexed keywords

ACICLOVIR; CEFAZOLIN; CHLORHEXIDINE; CIPROFLOXACIN; GRAMICIDIN; HOMATROPINE; KETOCONAZOLE; NEOMYCIN; OFLOXACIN; POLYMYXIN B; PREDNISOLONE; PREDNISOLONE ACETATE; TOBRAMYCIN;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; ADULT; ARTICLE; CASE REPORT; CORNEA DISEASE; CORNEA STROMA; CORNEA ULCER; CORNEAL BIOPSY; CORNEAL SCRAPING; CYST; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HYPOPYON; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; SCAR FORMATION; TROPHOZOITE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ACANTHAMOEBA KERATITIS; ADMINISTRATION, TOPICAL; ANTIPROTOZOAL AGENTS; CHLORHEXIDINE; CORNEAL STROMA; HUMANS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; TIME FACTORS;

EID: 38549137278     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31815b82a2     Document Type: Article

References (19)

1. Russell AD, Furr JR, Maillard JY. Microbial susceptibility and resistance to biocides. Am Soc Microbiol News. 1997;63:481-487.
2. Meisler DM, Rutherford I. Acanthamoeba and disinfection of soft contact lenses. Rev Infect Dis. 1991;13:S410-S412.
3. Borazjani RN, Kilvington S. Efficacy of multipurpose solutions against Acanthamoeba species. Contact Lens Anterior Eye. 2005;28:169-175.
4. Kumar R, Lloyd D. Recent advances in the treatment of Acanthamoeba keratitis. Clin Infect Dis. 2002;35:434-441.
5. Joslin CE, Tu EY, McMahon TT, et al. Epidemiological characteristics of a Chicago-area Acanthamoeba keratitis outbreak. Am J Ophthalmol. 2006;142:212-217.
6. Claerhout I, Goegebuer A, Van Den Broecke C, et al. Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch Clin Exp Ophthalmol. 2004;242:648-653.
7. Parmar DN, Awwad ST, Petroll WM, et al. Tandem scanning confocal corneal microscopy in the diagnosis of suspected Acanthamoeba keratitis. Ophthalmology. 2006;113:538-547.
8. Nakano E, Oliveira M, Portellinha W, et al. Confocal microscopy in early diagnosis of Acanthamoeba keratitis. J Refract Surg. 2004;20(5 suppl):S737-S740.
9. Kosrirukvongs P, Wanachiwanawin D, Visvesvara GS. Treatment of Acanthamoeba keratitis with chlorhexidine. Ophthalmology. 1999;106:798-802.
10. Hargrave SL, McCulley JP, Husseini Z, et al. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis. Ophthalmology. 1999;106:952-957.
11. Wright P, Warhurst D, Jones BR. Acanthamoeba keratitis successfully treated medically. Br J Ophthalmol. 1985;69:778-782.
12. Hay J, Kirkness CM, Seal DV, et al. Drug resistance and Acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy. Eye. 1994;8:555-563.
13. Ficker L, Seal D, Warhurst D, et al. Acanthamoeba keratitis - resistance to medical therapy. Eye. 1990;4:835-838.
14. Illingworth CD, Cook SD. Acanthamoeba keratitis. Surv Ophthalmol. 1998;42:493-508.
15. Mathers W. Use of higher medication concentrations in the treatment of acanthamoeba keratitis. Arch Ophthalmol. 2006;124:923.
16. Yang YF, Matheson M, Dart JKG, et al. Persistence of Acanthamoeba antigen following Acanthamoeba keratitis. Br J Ophthalmol. 2001;85:277-280.
17. Perez-Santonja JJ, Kilvington S, Hughes R, et al. Persistently culture positive Acanthamoeba keratitis. In vivo resistance and in vitro sensitivity. Ophthalmology. 2003;110:1593-1600.
18. Leher HF, Alizadeh H, Taylor WM, et al. Role of mucosal IgA in the resistance to Acanthamoeba keratitis. Invest Ophthalmol Vis Sci. 1998;39:2666-2673.
19. Alizadeh H, Apte S, El-Agha MSH, et al. Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis. Cornea. 2001;20:622-627.